Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world cohort study of lorlatinib-associated hyperlipidemia
ChiCTR2400092915Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Peking University Third Hospital. Primary endpoints: 3-month lipid concentrations, high-sensitivity C-reactive protein and 3 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400092915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092915.